Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug ...
MedPage Today on MSN
Drug combo for lung cancer beats pembrolizumab in first-line trial
Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expres ...
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ...
A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...
OptiTROP-Lung05 randomized 413 untreated, PD-L1 ≥1% advanced NSCLC patients without EGFR/ALK alterations to sac-TMT+pembrolizumab versus pembrolizumab; primary endpoint was PFS. Median PFS was not ...
Merck's TroFuse-005 Trial Evaluating Sac-TMT Met Primary Endpoints of OS and PFS in Certain Patients With Advanced or ...
The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...
CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology (ASCO) ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III ...
MSD's TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), licensed from China's Kelun-Biotech, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results